An interventional study of · Dex-Lido solution: Dexmedetomidine 100 μg/mL (concentration) was diluted with 2% lidocaine to achieve final concentration of dexmedetomidine 1 μg/kg in 5 mL total volume and · Lido solution: 2% lidocaine, 5 mL in Cough Suppression and Thyroidectomy, sponsored by Sohag University. Active, not recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Sohag University · Not applicable, Interventional, and Health services research
Study Hypothesis: The combination of dexmedetomidine and lidocaine administered as laryngopharyngeal topical spray provides superior suppression of extubation cough reflex compared to lidocaine alone or placebo, without compromising recovery or increasing adverse events
427 studies on the registry are indexed under Cough; 67 are open to participants now.
This study's planned enrollment of 120 is above the median of 80 across 319 interventional studies indexed under Cough.
Browse Cough studies →Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patients aged 18-65 years
Exclusion Criteria:
Known allergy or to dexmedetomidine, lidocaine, or study medications
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Received topical spray containing dexmedetomidine 1 μg/kg combined with 2% lidocaine (total volume 5 mL)
Drug: · Dex-Lido solution: Dexmedetomidine 100 μg/mL (concentration) was diluted with 2% lidocaine to achieve final concentration of dexmedetomidine 1 μg/kg in 5 mL total volume
Received topical spray containing 2% lidocaine alone (5 mL)
Drug: · Lido solution: 2% lidocaine, 5 mL
Received topical spray containing 0.9% normal saline (5 mL)
Drug: · Control solution: 0.9% normal saline, 5 mL
* Dex-Lido solution: Dexmedetomidine 100 μg/mL (concentration) was diluted with 2% lidocaine to achieve final concentration of dexmedetomidine 1 μg/kg in 5 mL total volume * Lido solution: 2% lidocaine, 5 mL * Control solution: 0.9% normal saline, 5 mL All solutions were prepared under aseptic conditions immediately before use and loaded into identical 5 mL syringes attached to a mucosal atomization device (MADgic™, Teleflex Medical) capable of delivering fine-particle spray.
· Lido solution: 2% lidocaine, 5 mL All solutions were prepared under aseptic conditions immediately before use and loaded into identical 5 mL syringes attached to a mucosal atomization device (MADgic™, Teleflex Medical) capable of delivering fine-particle spray.
· Control solution: 0.9% normal saline, 5 mL All solutions were prepared under aseptic conditions immediately before use and loaded into identical 5 mL syringes attached to a mucosal atomization device (MADgic™, Teleflex Medical) capable of delivering fine-particle spray.
Incidence of cough reflex during extubation
any visible or audible cough occurring from the time of endotracheal tube cuff deflation until 2 minutes following complete tube removal.
Time frame: 2 minutes following complete tube extubation
Cough Severity
Graded on a 4-point scale\]: * Grade 0: No cough * Grade 1: Single cough (mild) * Grade 2: Multiple coughs lasting \<5 seconds (moderate) * Grade 3: Sustained coughing \>5 seconds or severe paroxysms (severe)
Time frame: 10 minutes post extubations
Postoperative Sore Throat
using a 0-10 numerical rating scale (0 = no sore throat, 10 = worst imaginable sore throat) * Incidence of moderate-to-severe sore throat (score ≥4
Time frame: at 1, 6, 24, and 48 hours postoperatively
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.